Veracyte Stock Z Score

VCYT Stock

USD 25.02 0.23 0.91%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Veracyte Piotroski F Score and Veracyte Valuation analysis.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Build AI portfolio with Veracyte Stock

At this time, Veracyte's Capital Surpluse is comparatively stable compared to the past year. Capital Lease Obligations is likely to gain to about 53.3 M in 2025, despite the fact that Change In Working Capital is likely to grow to (20.3 M). At this time, Veracyte's Research Development is comparatively stable compared to the past year. EBITDA is likely to gain to about 51.7 M in 2025, whereas Reconciled Depreciation is likely to drop slightly above 16 M in 2025.

Veracyte Company Z Score Analysis

Veracyte's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Veracyte Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Veracyte is extremely important. It helps to project a fair market value of Veracyte Stock properly, considering its historical fundamentals such as Z Score. Since Veracyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Veracyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Veracyte's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Term Investments	Intangible Assets	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.68	-0.89	0.79	0.98	0.93	0.87	0.82	0.97	0.74	0.83	0.9	-0.49	0.98	-0.49	1.0	0.56	-0.43	0.03	0.76	0.84	0.75	0.98
Total Stockholder Equity	1.0		-0.69	-0.88	0.79	0.98	0.92	0.87	0.82	0.97	0.73	0.84	0.9	-0.5	0.98	-0.5	1.0	0.56	-0.44	0.02	0.76	0.84	0.75	0.98
Net Debt	-0.68	-0.69		0.7	-0.45	-0.68	-0.57	-0.93	-0.77	-0.58	-0.42	-0.59	-0.85	0.52	-0.53	0.52	-0.69	-0.7	0.49	0.2	-0.3	-0.62	-0.97	-0.76
Retained Earnings	-0.89	-0.88	0.7		-0.69	-0.94	-0.87	-0.85	-0.9	-0.91	-0.62	-0.75	-0.84	0.24	-0.83	0.24	-0.9	-0.7	0.27	-0.14	-0.52	-0.79	-0.78	-0.89
Accounts Payable	0.79	0.79	-0.45	-0.69		0.75	0.67	0.55	0.76	0.79	0.33	0.81	0.58	-0.4	0.82	-0.4	0.76	0.3	-0.32	0.02	0.78	0.57	0.45	0.78
Net Receivables	0.98	0.98	-0.68	-0.94	0.75		0.94	0.88	0.88	0.97	0.73	0.83	0.89	-0.37	0.95	-0.37	0.98	0.64	-0.36	0.1	0.68	0.84	0.76	0.96
Total Liab	0.93	0.92	-0.57	-0.87	0.67	0.94		0.83	0.79	0.96	0.84	0.7	0.81	-0.25	0.9	-0.25	0.94	0.55	-0.25	0.23	0.62	0.8	0.66	0.88
Total Current Assets	0.87	0.87	-0.93	-0.85	0.55	0.88	0.83		0.84	0.81	0.7	0.67	0.95	-0.47	0.75	-0.47	0.88	0.7	-0.45	-0.04	0.44	0.81	0.95	0.89
Common Stock	0.82	0.82	-0.77	-0.9	0.76	0.88	0.79	0.84		0.83	0.47	0.82	0.77	-0.25	0.74	-0.25	0.82	0.77	-0.28	0.12	0.51	0.66	0.8	0.86
Property Plant Equipment	0.97	0.97	-0.58	-0.91	0.79	0.97	0.96	0.81	0.83		0.74	0.79	0.83	-0.33	0.97	-0.33	0.98	0.57	-0.29	0.17	0.72	0.82	0.65	0.94
Short Term Investments	0.74	0.73	-0.42	-0.62	0.33	0.73	0.84	0.7	0.47	0.74		0.4	0.76	-0.32	0.71	-0.32	0.76	0.31	-0.31	0.12	0.34	0.81	0.55	0.68
Intangible Assets	0.83	0.84	-0.59	-0.75	0.81	0.83	0.7	0.67	0.82	0.79	0.4		0.65	-0.45	0.8	-0.45	0.81	0.63	-0.39	0.0	0.84	0.51	0.63	0.85
Net Tangible Assets	0.9	0.9	-0.85	-0.84	0.58	0.89	0.81	0.95	0.77	0.83	0.76	0.65		-0.55	0.82	-0.55	0.91	0.57	-0.5	-0.09	0.45	0.93	0.9	0.92
Long Term Debt	-0.49	-0.5	0.52	0.24	-0.4	-0.37	-0.25	-0.47	-0.25	-0.33	-0.32	-0.45	-0.55		-0.46	1.0	-0.47	-0.14	0.79	0.6	-0.48	-0.43	-0.51	-0.55
Good Will	0.98	0.98	-0.53	-0.83	0.82	0.95	0.9	0.75	0.74	0.97	0.71	0.8	0.82	-0.46		-0.46	0.97	0.44	-0.4	0.06	0.81	0.82	0.61	0.94
Long Term Debt Total	-0.49	-0.5	0.52	0.24	-0.4	-0.37	-0.25	-0.47	-0.25	-0.33	-0.32	-0.45	-0.55	1.0	-0.46		-0.47	-0.14	0.79	0.6	-0.48	-0.43	-0.51	-0.55
Capital Surpluse	1.0	1.0	-0.69	-0.9	0.76	0.98	0.94	0.88	0.82	0.98	0.76	0.81	0.91	-0.47	0.97	-0.47		0.57	-0.43	0.04	0.72	0.86	0.76	0.98
Deferred Long Term Liab	0.56	0.56	-0.7	-0.7	0.3	0.64	0.55	0.7	0.77	0.57	0.31	0.63	0.57	-0.14	0.44	-0.14	0.57		-0.12	0.17	0.3	0.37	0.72	0.61
Short Long Term Debt	-0.43	-0.44	0.49	0.27	-0.32	-0.36	-0.25	-0.45	-0.28	-0.29	-0.31	-0.39	-0.5	0.79	-0.4	0.79	-0.43	-0.12		0.86	-0.39	-0.39	-0.49	-0.47
Short Term Debt	0.03	0.02	0.2	-0.14	0.02	0.1	0.23	-0.04	0.12	0.17	0.12	0.0	-0.09	0.6	0.06	0.6	0.04	0.17	0.86		-0.07	0.01	-0.14	0.0
Current Deferred Revenue	0.76	0.76	-0.3	-0.52	0.78	0.68	0.62	0.44	0.51	0.72	0.34	0.84	0.45	-0.48	0.81	-0.48	0.72	0.3	-0.39	-0.07		0.35	0.32	0.71
Net Invested Capital	0.84	0.84	-0.62	-0.79	0.57	0.84	0.8	0.81	0.66	0.82	0.81	0.51	0.93	-0.43	0.82	-0.43	0.86	0.37	-0.39	0.01	0.35		0.7	0.84
Net Working Capital	0.75	0.75	-0.97	-0.78	0.45	0.76	0.66	0.95	0.8	0.65	0.55	0.63	0.9	-0.51	0.61	-0.51	0.76	0.72	-0.49	-0.14	0.32	0.7		0.82
Capital Stock	0.98	0.98	-0.76	-0.89	0.78	0.96	0.88	0.89	0.86	0.94	0.68	0.85	0.92	-0.55	0.94	-0.55	0.98	0.61	-0.47	0.0	0.71	0.84	0.82

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Veracyte

As per the company's disclosures, Veracyte has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Veracyte Current Valuation Drivers

We derive many important indicators used in calculating different scores of Veracyte from analyzing Veracyte's financial statements. These drivers represent accounts that assess Veracyte's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Veracyte's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	2.6B	2.8B	1.7B	2.0B	3.0B	3.2B
Enterprise Value	2.3B	2.6B	1.6B	1.8B	2.8B	3.0B

Veracyte ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Veracyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Veracyte's managers, analysts, and investors.

Environmental

Governance

Social

Veracyte Institutional Holders

Institutional Holdings refers to the ownership stake in Veracyte that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Veracyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Veracyte's value.

		Shares
Geode Capital Management, Llc	2025-03-31	1.9 M
Driehaus Capital Management Llc	2025-03-31	1.4 M
Gw&k Investment Management, Llc	2025-03-31	1.3 M
Nuveen Asset Management, Llc	2024-12-31	1.2 M
Bank Of America Corp	2025-03-31	1.2 M
Nuveen, Llc	2025-03-31	1.1 M
Goldman Sachs Group Inc	2025-03-31	1 M
Northern Trust Corp	2025-03-31	1 M
First Trust Advisors L.p.	2025-03-31	1 M
Vanguard Group Inc	2025-03-31	8.3 M
Blackrock Inc	2025-03-31	7.5 M

Veracyte Fundamentals

	Return On Equity	0.0286
	Return On Asset	0.0194
	Profit Margin	0.07 %
	Operating Margin	0.07 %
	Current Valuation	1.74 B
	Shares Outstanding	78.31 M
	Shares Owned By Insiders	0.54 %
	Shares Owned By Institutions	99.46 %
	Number Of Shares Shorted	6.11 M
	Price To Earning	(10.61) X
	Price To Book	1.65 X
	Price To Sales	4.27 X
	Revenue	445.76 M
	Gross Profit	326.41 M
	EBITDA	49.2 M
	Net Income	24.14 M
	Cash And Equivalents	170.11 M
	Cash Per Share	2.37 X
	Total Debt	50.74 M
	Debt To Equity	0.02 %
	Current Ratio	4.09 X
	Book Value Per Share	15.26 X
	Cash Flow From Operations	75.1 M
	Short Ratio	6.38 X
	Earnings Per Share	0.42 X
	Target Price	40.33
	Number Of Employees	824
	Beta	2.07
	Market Capitalization	1.98 B
	Total Asset	1.3 B
	Retained Earnings	(443.98 M)
	Working Capital	293.63 M
	Current Asset	47.91 M
	Current Liabilities	14.72 M
	Net Asset	1.3 B

About Veracyte Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Veracyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veracyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veracyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Veracyte Stock Z Score

Veracyte Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Veracyte Z Score Driver Correlations

Veracyte Current Valuation Drivers

Veracyte ESG Sustainability

Veracyte Institutional Holders

Veracyte Fundamentals

About Veracyte Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Veracyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY